⏳ Fetching live dividend data...
Home › Calculator › SRNE Dividend Calculator 2026
Sorrento Therapeutics, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SRNE → $3.690270327864796e+47M in 10 years · $30,752,245,224,334,260,000,000,000,000,000,000,000,000,000,000,000,000.00/month
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SRNE position with:
Real after-tax yield depends on where you live and how you hold SRNE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 340000.00% | 339997.20% | $34,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 320000.00% | 319997.20% | $32,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 365000.00% | 364997.20% | $36,500,000 / yr |
| 🇨🇦 TFSA | 0% | 400000.00% | 399997.20% | $40,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 300000.00% | 299997.20% | $30,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 340000.00% | 339997.20% | $34,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 280000.00% | 279997.20% | $28,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 294500.00% | 294497.20% | $29,450,000 / yr |
| 🇫🇷 FR Taxable | 30% | 280000.00% | 279997.20% | $28,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SRNE pays quarterly — 4 times per year. Next ex-div: TBD.
How SRNE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SRNE sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| X-InTheMoney | 2023-03-17 | 19,500 | $0.80 | $15.7K | ||
| D-Return | 2023-03-17 | 195 | $0.80 | $157.00 | ||
| X-InTheMoney | 2022-12-21 | 300 | $5.50 | $1.6K | ||
| X-InTheMoney | 2022-12-02 | 200 | $5.50 | $1.1K | ||
| X-InTheMoney | 2022-12-02 | 2 | — | — | ||
| X-InTheMoney | 2022-12-21 | 3 | — | — | ||
| A-Award | 2022-12-15 | 1,500,000 | — | — | ||
| Buy | 2022-09-07 | 88,888 | $2.02 | $179.3K | ||
| Buy | 2022-09-07 | 759 | $12.00 | $9.1K | ||
| Buy | 2022-09-07 | 129 | $12.00 | $1.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SRNE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →